<SEC-DOCUMENT>0001193125-23-142108.txt : 20230511
<SEC-HEADER>0001193125-23-142108.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230511164314
ACCESSION NUMBER:		0001193125-23-142108
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-271431
		FILM NUMBER:		23911786

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d508302d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR>Registration No. 333-271431 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus supplement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To prospectus dated May&nbsp;2, 2023) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g508302g27s54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered
into a sales agreement (the &#147;sales agreement&#148;), with Cowen and Company, LLC (&#147;Cowen&#148;), relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell
shares of our common stock having an aggregate offering price of up to $100,000,000 from time to time through Cowen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
quoted on The Nasdaq Global Market under the symbol &#147;ADVM.&#148; The last reported sale price of the common stock on May&nbsp;10, 2023 was $0.849 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be an &#147;at
the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Cowen is not required to sell any specific number or dollar amount of securities, but will act as a
sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cowen and us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation to Cowen for sales of common stock sold pursuant to the sales agreement will be up to 3.0% of the gross proceeds of any
shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cowen will
be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of
1934, as amended (the &#147;Exchange Act&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>See &#147;<A HREF="#srom508302_3">Risk Factors</A>&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-3</FONT> of this prospectus supplement and page 5 of the accompanying prospectus to read about factors you should consider before buying shares of the common stock. </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon
the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen
</B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement dated May&nbsp;11, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PROSPECTUS SUPPLEMENT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_1">About This Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_2">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_6">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_7">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_8">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_9">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom508302_10">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PROSPECTUS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_6">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_7">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_8">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_9">Legal Ownership of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_10">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_12">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_13">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_14">Incorporation of Certain Information By Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide any information or to make any representations other than those
contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectuses we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. This prospectus supplement and the accompanying prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information
contained in this prospectus supplement and the accompanying prospectus is current only as of the respective dates of such documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus dated May&nbsp;2, 2023 form part of a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange Commission (&#147;SEC&#148;), utilizing a &#147;shelf&#148; registration process. This document is in two parts. The first part is this prospectus supplement, which
describes the specific terms of this common stock offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part, the accompanying prospectus, provides
more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information
contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one
of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in the accompanying prospectus&#151;the statement in the document having the later date modifies or
supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is
filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and
should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be
relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not, and Cowen has not, authorized anyone to provide any
information other than that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus that we have authorized for use in connection with this offering. We and Cowen take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer
to purchase, the securities offered by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. The
information contained in this prospectus supplement, the accompanying prospectus, any free writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference herein or therein, is
accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock. It is important for you to read and consider all information
contained in this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference herein and therein, in making
your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections titled &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Certain Information by
Reference&#148; in this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Cowen are offering to sell, and seeking offers to
buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be
restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and
the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a
solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated herein or as the context otherwise requires, references in
this prospectus supplement to &#147;Adverum,&#148; &#147;the company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references refer to Adverum Biotechnologies, Inc., a corporation under the laws of the State of Delaware, and its
wholly owned subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by
reference into this prospectus supplement. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and
this offering, you should read and consider carefully the more detailed information included or incorporated by reference in this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in
connection with this offering, including the factors described in the section titled &#147;Risk Factors&#148; in this prospectus supplement beginning on page <FONT STYLE="white-space:nowrap">S-3</FONT> and in our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as in any free writing prospectus we have authorized for use in connection with this offering. You also should carefully read
the other information incorporated by reference into this prospectus supplement and the accompanying prospectus, including our financial statements, other information and the exhibits to the registration statement of which this prospectus supplement
and the accompanying prospectus are a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. We
discover and develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include novel vector evaluation, cassette engineering, and ocular <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> nonclinical and clinical development. In addition, we have <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing expertise, specifically in scalable process development, assay development, and
current Good Manufacturing Practices (&#147;GMP&#148;) quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, ixoberogene soroparvovec <FONT
STYLE="white-space:nowrap">(&#147;Ixo-vec&#148;),</FONT> formerly referred to as <FONT STYLE="white-space:nowrap">ADVM-022,</FONT> is a single, <FONT STYLE="white-space:nowrap">in-office</FONT> intravitreal (&#147;IVT&#148;) injection gene therapy
product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial
growth factor (&#147;VEGF&#148;) IVT injections. <FONT STYLE="white-space:nowrap">Ixo-vec</FONT> utilizes an engineered, proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression
cassette capable of transducing retinal cells after a single <FONT STYLE="white-space:nowrap">in-office</FONT> IVT injection. This product is intended to improve both real-world vision and quality of life outcomes for patients. <FONT
STYLE="white-space:nowrap">Ixo-vec</FONT> is currently being developed for the treatment of patients with wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (&#147;wet AMD&#148;) who are responsive to anti-VEGF therapy.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware in 2006 under the name &#147;Avalanche Biotechnologies, Inc.&#148; We completed the initial public offering of our common stock in August 2014. On May&nbsp;11, 2016, upon the completion of our acquisition of Annapurna
Therapeutics SAS, we changed our name to &#147;Adverum Biotechnologies, Inc.&#148; Our common stock is currently listed on The Nasdaq Global Market under the symbol &#147;ADVM.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 100 Cardinal Way, Redwood City, CA 94063, and our telephone number is <FONT
STYLE="white-space:nowrap">(650)&nbsp;656-9323.&nbsp;Our</FONT> website address is www.adverum.com. The information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive
textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All brand names or trademarks appearing in this prospectus supplement and accompanying prospectus are the
property of their respective holders. Use or display by us of other parties&#146; trademarks, trade dress, or products in this prospectus supplement and the accompanying prospectus is not intended to, and does not, imply a relationship with, or
endorsements or sponsorship of, us by the trademark or trade dress owners. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Offering </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="60%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares of our common stock having an aggregate offering price of up to $100,000,000.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to 218,358,912 shares (as more fully described in the notes following this table), assuming sales of 117,785,630 shares of our common stock in this offering at an offering price of $0.849 per share, the last reported sale price
of our common stock on The Nasdaq Global Market on May&nbsp;10, 2023. The actual number of shares issued will vary depending on the sales price under this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manner of offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;At the market offering&#148; that may be made from time to time through our sales agent, Cowen. See &#147;Plan of Distribution&#148; on page <FONT STYLE="white-space:nowrap">S-7.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We currently intend to use the net proceeds from this offering for general corporate purposes. General corporate purposes may include, without limitation, the research and development of our lead program, <FONT
STYLE="white-space:nowrap">Ixo-vec,</FONT> the rest of our gene therapy pipeline and our AAV vector platform, process development and manufacturing improvements, acquisitions or <FONT STYLE="white-space:nowrap">in-licenses</FONT> of complementary
businesses, programs or technology, working capital and capital expenditures. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investing in our common stock involves significant risks. See &#147;Risk Factors&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-3</FONT> of this prospectus supplement, and under similar headings in other documents
incorporated by reference into this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Nasdaq Global Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Our shares are listed on The Nasdaq Global Market under the symbol &#147;ADVM.&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding after the offering is based on the number of shares
outstanding as of March&nbsp;31, 2023. As of that date, we had 100,573,282 shares of common stock outstanding, excluding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">23,306,932 shares of common stock underlying options outstanding as of March&nbsp;31, 2023, at a weighted average
exercise price of $4.87 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,738,587 shares of common stock issuable upon the vesting of restricted stock units outstanding as of
March&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,720,207 shares of common stock available for future grant under our equity incentive plans as of March&nbsp;31,
2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,043,481 shares of common stock available for future issuance under our employee stock purchase plan as of
March&nbsp;31, 2023. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors described below, as well as
the risk factors described under the caption &#147;Risk Factors&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and the other
information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, including our financial statements and the related notes, as may be updated by our subsequent filings under the Exchange Act, and in
any free writing prospectus that we have authorized for use in connection with this offering before acquiring shares of our common stock. These risks could have a material and adverse impact on our business, results of operations, financial
condition and growth prospects, which may cause the trading price of our common stock to decline and you could lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management will
have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
management will have broad discretion in the application of the net proceeds from this offering, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Our failure to apply these
funds effectively could have a material adverse effect on our business and cause the price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience
dilution if we issue additional equity securities in future fundraising transactions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To raise additional capital, we may in the
future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any
other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share
at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. Further, we have a
significant number of stock options, warrants and restricted stock units outstanding. The exercise of outstanding stock options and warrants and vesting of restricted stock units may result in further dilution of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is not possible to predict the actual number of shares we will sell under the sales agreement, or the gross proceeds resulting from those sales.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver
instruction to Cowen to sell shares of our common stock at any time throughout the term of the sales agreement. The number of shares that are sold through Cowen after our instruction will depend on a number of factors, including the market price of
our common stock during the sales period, the limits we set with Cowen in any instruction to sell shares, and the demand for our common stock during the sales period. Because the price per share of each share sold will fluctuate during this
offering, it is not currently possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with those sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The common stock offered hereby will be sold in &#147;at the market offerings,&#148; and investors who buy shares at different times
will likely pay different prices. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will likely pay different
prices, and so may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold in this offering. In addition,
subject to the final determination by our board of directors, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result
of sales made at prices lower than the prices they paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the statements in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference and any free
writing prospectus that we have authorized for use in connection with this offering are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. These statements are based on
our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#146;s or our industry&#146;s results, levels of
activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Forward-looking statements may
include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing, costs and results of preclinical studies and any clinical trials for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our viral vector manufacturing and delivery capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development expenses could fluctuate and may increase; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings, designations and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to explore potential applications of our gene therapy platform in other indications in highly prevalent
ocular diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the clinical effectiveness of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation regarding the potential market sizes for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of our strategic collaborations and our ability to enter into strategic arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, our financial position, capital requirements, uses of cash and
needs for additional financing and the period for which our cash resources will be sufficient to meet our operating requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the use of proceeds from this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety, efficacy and projected development timeline and commercial potential of any product candidates.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148;
&#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;predicts,&#148; &#147;potential&#148; and similar
expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &#147;Risk Factors&#148; contained in this prospectus supplement and in any free writing prospectuses we may authorize for
use in connection with this offering. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to
update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such
forward-looking statements. You should read this prospectus supplement and accompanying prospectus together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the
forward-looking statements in the foregoing documents by these cautionary statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148;
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis
for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements
are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $100.0&nbsp;million from time to time. Because there
is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares
under or fully utilize the sales agreement with Cowen as a source of financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net
proceeds from this offering. We currently intend to use the net proceeds from this offering for general corporate purposes. General corporate purposes may include, without limitation, the research and development of our lead program, <FONT
STYLE="white-space:nowrap">Ixo-vec,</FONT> the rest of our gene therapy pipeline and our AAV vector platform, process development and manufacturing improvements, acquisitions or <FONT STYLE="white-space:nowrap">in-licenses</FONT> of complementary
businesses, programs or technology, working capital and capital expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending their use, we plan to invest the net proceeds from
this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a sales agreement with Cowen, under which we may issue and sell from time to time up to $100,000,000 of our common stock
through Cowen as our sales agent. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) under the Securities Act, including sales made
directly on The Nasdaq Global Market or any other trading market for our common stock. If authorized by us in writing, Cowen may purchase shares of our common stock as principal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cowen will offer our common stock subject to the terms and conditions of the sales agreement on a daily basis or as otherwise agreed upon by
us and Cowen. We will designate the maximum amount of common stock to be sold through Cowen on a daily basis or otherwise determine such maximum amount together with Cowen. Subject to the terms and conditions of the sales agreement, Cowen will use
its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct Cowen not to sell common stock if the sales cannot be effected at or above the price designated by us in any such
instruction. Cowen or we may suspend the offering of our common stock being made through Cowen under the sales agreement upon proper notice to the other party. Cowen and we each have the right, by giving written notice as specified in the sales
agreement, to terminate the sales agreement in each party&#146;s sole discretion at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate compensation payable to Cowen
as sales agent equals up to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. In addition, we have agreed to reimburse Cowen for fees and disbursements related to its legal counsel in an amount not to
exceed $75,000, and for certain other expenses, including Cowen&#146;s FINRA counsel fees in an amount up to $10,000. We estimate that the total expenses of the offering payable by us, excluding commissions payable to Cowen under the sales
agreement, will be approximately $550,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining sales proceeds, after deducting any expenses payable by us and any transaction
fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cowen will provide written confirmation to us following the close of trading on The Nasdaq Global Market on each day in which common stock is
sold through it as sales agent under the sales agreement. Each confirmation will include the number of shares of common stock sold through it as sales agent on that day, the volume weighted average price of the shares sold, the percentage of the
daily trading volume and the net proceeds to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will report at least quarterly the number of shares of common stock sold through
Cowen under the sales agreement, the net proceeds to us and the compensation paid by us to Cowen in connection with the sales of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for sales of common stock will occur, unless the parties agree otherwise or otherwise required by law, on the second trading day
following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sales of our common stock on our behalf, Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of
the Securities Act, and the compensation paid to Cowen will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and contribution to Cowen against certain liabilities, including
liabilities under the Securities Act. As sales agent, Cowen will not engage in any transactions that stabilizes our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on The Nasdaq Global Market and trades under the symbol &#147;ADVM.&#148; The transfer agent of our common stock is American Stock Transfer&nbsp;&amp; Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cowen and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for
which services they have received and, may in the future receive, customary fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_7"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP will pass upon the validity of the common stock offered hereby. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is representing
Cowen in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_8"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, as set forth in their report, which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement.
Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_9"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of the registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> we filed with the SEC under the Securities Act and do not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus supplement or the
accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents
incorporated by reference into this prospectus supplement and the accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file
annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a website at www.adverum.com. Information contained in or accessible through our website does not constitute a part of this
prospectus supplement or the accompanying prospectus and is not incorporated by reference into this prospectus supplement or the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom508302_10"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement and the accompanying prospectus. Information in this prospectus supplement
and the accompanying prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement and the accompanying prospectus, while information that we file later with the SEC will
automatically update and supersede the information in this prospectus supplement and the accompanying prospectus. We incorporate by reference into this prospectus supplement, the accompanying prospectus and the registration statement of which this
prospectus supplement and the accompanying prospectus are a part the information or documents listed below that we have filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36579),</FONT> excluding any portions of any
Form <FONT STYLE="white-space:nowrap">8-K</FONT> that are not deemed &#147;filed&#148; pursuant to the General Instructions of <FONT STYLE="white-space:nowrap">Form&nbsp;8-K:</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501756/000162828023009899/advm-20221231.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A> for the year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;30, 2023 (our <FONT STYLE="white-space:nowrap">&#147;Form&nbsp;10-K&#148;);</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference in our
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;from</FONT> our proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1501756/000114036123020185/ny20007145x2_def14a.htm">Schedule&nbsp;14A</A> filed with the SEC on April&nbsp;25,
2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501756/000162828023017564/advm-20230331.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT></A> for the quarter ended March&nbsp;31, 2023, filed with the SEC on May&nbsp;11, 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock set forth in our registration statement on<A HREF="http://www.sec.gov/Archives/edgar/data/1501756/000119312514282544/d765259d8a12b.htm">
<FONT STYLE="white-space:nowrap">&nbsp;Form&nbsp;8-A</FONT></A>, filed with the SEC on July&nbsp;
28, 2014, including any amendment or report filed for the purpose of updating such description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1501756/000162828021003623/advm-20201231xexx42.htm">Exhibit 4.2</A> to our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;1, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act. Information in such future filings updates and supplements the information provided in this prospectus supplement and the accompanying prospectus. Any statements in any such future filings will automatically
be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such
earlier statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or
telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adverum Biotechnologies, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 Cardinal Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Redwood City, CA
94063 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650) <FONT STYLE="white-space:nowrap">656-9323</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g508302g01p03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$300,000,000 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time we, Adverum Biotechnologies, Inc., may offer and sell up to an aggregate amount of $300,000,000 of any combination of the securities described in this prospectus, either individually or in combination. We may also offer common stock or
preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one
or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should
carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any of the securities being offered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Market under the symbol &#147;ADVM.&#148; On April&nbsp;24, 2023, the last reported sale price
of our common stock was $0.9020 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on the Nasdaq Global Market or other securities exchange of the securities covered by the
applicable prospectus supplement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B><I>Investing in our securities involves a high degree of risk. Before making an investment decision, you should review carefully the risks
described under the heading &#147;<A HREF="#rom508302_3">Risk Factors</A>&#148; on page&nbsp;5 of this prospectus and any similar section contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized for
use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this prospectus. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers,
on a continuous or delayed basis. The supplements to this prospectus will provide the specific terms of the plan of distribution. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being
delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to
receive from such sale will also be set forth in a prospectus supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is May&nbsp;2, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom508302_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission, or SEC, using a &#147;shelf&#148; registration process. Under this shelf registration statement, we may, from time to time, offer and sell, either individually or in combination, in one or more offerings, up to a total dollar
amount of $300,000,000 of any combination of the securities described in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general
description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also authorize one or more
free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or
change any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to read carefully this prospectus, any applicable prospectus supplement and any free writing
prospectuses we have authorized for use in connection with a specific offering, together with the information incorporated herein by reference as described under the heading &#147;Incorporation of Certain Information by Reference,&#148; before
buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a
prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this prospectus and
any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different or additional
information. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus, the accompanying prospectus supplement or in any related free writing prospectus that we may authorize to be
provided to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information appearing in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as
of the date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable
prospectus supplement or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent
industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information.
Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on
various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated
by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains
summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below
under the section entitled &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information appearing elsewhere in this prospectus or incorporated by reference in this prospectus and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks
of investing in our securities discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by
reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.
</I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adverum Biotechnologies, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverum is a clinical-stage
company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. We discover and develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a
therapeutic protein. Our core capabilities include novel vector evaluation, cassette engineering, and ocular <FONT STYLE="white-space:nowrap">IND-enabling</FONT> nonclinical and clinical development. In addition, we have <FONT
STYLE="white-space:nowrap">in-house</FONT> manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#147;GMP&#148;) quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, ixoberogene soroparvovec <FONT STYLE="white-space:nowrap">(&#147;Ixo-vec&#148;),</FONT> formerly referred to as <FONT
STYLE="white-space:nowrap">ADVM-022,</FONT> is a single, <FONT STYLE="white-space:nowrap">in-office</FONT> intravitreal (&#147;IVT&#148;) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept
associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (&#147;VEGF&#148;) IVT injections.
<FONT STYLE="white-space:nowrap">Ixo-vec</FONT> utilizes an engineered, proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette capable of transducing retinal cells after a
single <FONT STYLE="white-space:nowrap">in-office</FONT> IVT injection. This product is intended to improve both real-world vision and quality of life outcomes for patients. <FONT STYLE="white-space:nowrap">Ixo-vec</FONT> is currently being
developed for the treatment of patients with wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (&#147;wet AMD&#148;) who are responsive to anti-VEGF therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware in 2006 under the name &#147;Avalanche Biotechnologies, Inc.&#148; We completed the initial public offering of our common stock in August 2014. On May&nbsp;11, 2016, upon the completion of our acquisition of Annapurna
Therapeutics SAS, we changed our name to &#147;Adverum Biotechnologies, Inc.&#148; Our common stock is currently listed on The Nasdaq Global Market under the symbol &#147;ADVM.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 100 Cardinal Way, Redwood City, CA 94063, and our telephone number is (650) <FONT
STYLE="white-space:nowrap">656-9323.</FONT> Our website address is www.adverum.com. The information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual
reference only. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such
securities, either individually or in combination, from time to time under this prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and on terms to be determined by market conditions at the time of any offering, up to a maximum aggregate sales price of $300,000,000. We may also offer common stock, preferred stock and/or debt
securities upon the exercise of warrants. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that
will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity date, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exercise, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material or special U.S. federal income tax considerations, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this
prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY&nbsp;NOT BE USED TO
CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors
or to or through agents, underwriters or dealers. We and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters, we will
include in the applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those agents or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net proceeds to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Common Stock</I>. We may issue shares of our common stock from time to time. The holders of our common stock are entitled to one vote for
each share held of record on all matters submitted to a vote of stockholders. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends as
may be declared by our board of directors out of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the
liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions
applicable to our common stock. In this prospectus, we have summarized certain general features of the common stock under &#147;Description of Capital Stock&#151;Common Stock.&#148; We urge you, however, to read the applicable prospectus supplement
(and any related free writing prospectus that we may authorize to be provided to you) related to any common stock being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock.</I> We may issue shares of our preferred stock from time to time, in one or more series. Our board of directors will
determine the designations, voting powers, preferences and rights of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or
repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for other securities.
Conversion may be mandatory or at your option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell any series of preferred stock under
this prospectus, we will fix the designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the certificate of
designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation
that contains the terms of the series of preferred stock we are offering. In this prospectus, we have summarized certain general features of the preferred stock under &#147;Description of Capital Stock&#151;Preferred Stock.&#148; We urge you,
however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation
that contains the terms of the applicable series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Debt Securities.</I> We may issue debt securities from time to
time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be
subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock
or other securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any debt securities
issued under this prospectus will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general
features of the debt securities under &#147;Description of Debt Securities.&#148; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series
of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental
indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we
file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants.</I> We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one
or more series. We may issue warrants independently or in combination with common stock, preferred stock and/or debt securities. In this prospectus, we have summarized certain general features of the warrants under &#147;Description of
Warrants.&#148; We urge you, however, to read the applicable prospectus supplement (and any </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as any warrant agreements and warrant certificates
that contain the terms of the warrants. We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a
part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as
applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any warrants issued under this prospectus may be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant
agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in
any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any,
for working capital, capital expenditures and other general corporate purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market under the symbol &#147;ADVM.&#148; The applicable prospectus supplement will contain
information, where applicable, as to other listings, if any, on the Nasdaq Global Market or other securities exchange of the securities covered by the applicable prospectus supplement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and discussed under the section entitled &#147;Risk Factors&#148; contained
in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings
with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in
connection with this offering. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors
that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of
these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment.
Please also read carefully the section below entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_4">
</A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents we have filed with the SEC that are
incorporated by reference contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, or the
Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be
materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our viral vector manufacturing and delivery capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development expenses could fluctuate and may increase; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory submissions, designations and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to explore potential applications of our gene therapy platform in other indications in highly prevalent
diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the clinical effectiveness of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation regarding the potential market sizes for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of our strategic collaborations and our ability to enter into strategic arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, our financial position, capital requirements, uses of cash and
needs for additional financing and the period for which our cash resources will be sufficient to meet our operating requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety, efficacy and projected development timeline and commercial potential of any product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the use of proceeds from any offering we may conduct. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148;
&#147;could,&#148; &#147;would,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;predicts,&#148; &#147;potential&#148; and similar expressions intended to
identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on
these forward-looking statements. We discuss in greater detail many of these risks under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement, in any free writing prospectuses we may authorize for use in connection
with a specific offering, and in our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto
reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing
the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means
that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus, any applicable prospectus supplement, together with the documents we have filed with the SEC that are incorporated by
reference and any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the
forward-looking statements in the foregoing documents by these cautionary statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148;
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_5"></A>USE OF PROCEEDS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in
connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for working capital, capital expenditures and other general corporate purposes, which may include costs
of funding future acquisitions or for any other purpose we describe in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 300,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred
stock, $0.0001 par value per share. A description of material terms and provisions of our certificate of incorporation and bylaws affecting the rights of holders of our capital stock is set forth below. The description is intended as a summary, and
is qualified in its entirety by reference to our certificate of incorporation and the bylaws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the
election of directors. In the election of directors, a plurality of the votes cast at a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting of stockholders is sufficient to elect a director. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting
shares are able to elect all of the directors. In all other matters, except as noted below under &#147;&#151;Amendment of our Amended and Restated Certificate of Incorporation or our Amended and Restated Bylaws&#148; and &#147;&#151;Election and
Removal of Directors&#148; and except where a higher threshold is required by law, a majority of the votes cast affirmatively or negatively (excluding abstentions and broker <FONT STYLE="white-space:nowrap">non-votes)</FONT> will decide such
matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled
to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event
of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the
satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our
common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject
to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation authorizes our board of directors, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions
thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation
of such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend
payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control of our company or other corporate action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as
well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference
from reports that we file with the SEC, the form of any certificate of designation that contains the terms of the series of preferred stock we are offering. We will describe in the applicable prospectus supplement the terms of the series of
preferred stock being offered, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares we are offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, period and payment date and method of calculation for dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if applicable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price,
or how it will be calculated, and the conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or
how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of material United States federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with
the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Provisions of our Certificate of Incorporation and Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law and our restated certificate of incorporation and our amended and restated bylaws contain provisions that could have the effect of
delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to
encourage persons seeking to acquire control of us to first negotiate with our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or
other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our charter
documents provide that a special meeting of stockholders may be called only by the secretary of our company at the direction of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for
election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Election and Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected
each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for
stockholders to replace a majority of the directors. Our charter documents provide that directors may be removed from office at any time (i)&nbsp;with cause by the affirmative vote of the holders of a majority of the voting power of all the then
outstanding shares of our voting stock entitled to vote at an election of directors or (ii)&nbsp;without cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and
<FONT STYLE="white-space:nowrap">two-thirds</FONT> percent <FONT STYLE="white-space:nowrap">(66-2/3%)</FONT> of the voting power of all the then outstanding shares of our voting stock entitled to vote at an election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in a business combination with any interested stockholder for a period of three years following the date the person became an interested stockholder,
with the following exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested holder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the
interested stockholder) those shares owned (a)&nbsp;by persons who are directors and also officers and (b)&nbsp;pursuant to employee stock plans in which employee participants do not have the right to determine confidentially whether shares held
subject to the plan will be tendered in a tender or exchange offer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 of the DGCL defines business combination to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
or any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL defines an &#147;interested
stockholder&#148; as an entity or person who, together with the entity&#146;s or person&#146;s affiliates and associates, beneficially owns, or is an affiliate of the corporation and within </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. A Delaware corporation may &#147;opt
out&#148; of these provisions with an express provision in its certificate of incorporation. We have not opted out of these provisions, which may as a result, discourage or prevent mergers or other takeover or change of control attempts of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of our Amended and Restated Certificate of Incorporation or our Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision making it
possible for our board of directors to issue preferred stock, or the amendment of any provision in our amended and restated bylaws (other than by action of the board of directors), would require approval by holders of at least 66 2/3% of our then
outstanding voting stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation
and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from
actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may
otherwise deem to be in their best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware as Sole and Exclusive Forum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the
sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of Adverum, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Adverum to us or our
stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine shall be the Court of Chancery of
the State of Delaware, in all cases subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">American
Stock Transfer&nbsp;&amp; Trust Company is the transfer agent and registrar for our common stock. The transfer agent and registrar&#146;s address is 6201 15th Avenue, Brooklyn, NY 11219. The main telephone number is (800) <FONT
STYLE="white-space:nowrap">937-5449.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on the Nasdaq Global Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market the symbol &#147;ADVM.&#148; The applicable prospectus supplement will contain
information, where applicable, as to any other listing, if any, on the Nasdaq Global Market or any securities market or other exchange of the preferred stock covered by such prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities
containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by
reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may
offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal
amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the
indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture as &#147;discount securities,&#148; which means they may be sold at a discount
below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue discount,&#148; or OID, for U.S. federal income tax purposes because of interest
payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in
part for other individual securities, and the depositary for such global security or securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the
terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or
exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include
provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of
our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of
default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a
notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the
last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the
unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each
issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall occur
and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered
the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the
trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90&nbsp;days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if
any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified
covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;Description of Debt Securities&#151;Consolidation,
Merger or Sale;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;Description of Debt Securities&#151;General&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the
rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be
deposited with, or on behalf of, The Depository Trust Company, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form
and as book-entry, a description of terms relating to any book entry securities will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of
the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any
registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will name in the
applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the
designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15&nbsp;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and
liabilities that it might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will
maintain a paying agent in each place of payment for the debt securities of a particular series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or
the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the
holder of the debt security thereafter may look only to us for payment thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except
to the extent that the Trust Indenture Act of 1939 is applicable. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements and in any related
free writing prospectuses that we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock
or debt securities and be issued in one or more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will
apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the
warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or additional terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as
exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of warrant and/or the warrant agreement and warrant certificate, as applicable, that describe the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. The following
summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any
supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this
prospectus, as well as any related free writing prospectuses, and the complete form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the
applicable prospectus supplement the terms of the series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be
exercised at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust
office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or
the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise
specify in the applicable prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or
relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the
applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder
of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss
below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of
themselves or their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security.
Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all
payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so
under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global
security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect
holders, and not holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a global security or issue securities in <FONT STYLE="white-space:nowrap">non-global</FONT> form. In these cases, investors
may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the
investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those
securities to them. These institutions pass along the payments they receive to their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street
name will be indirect holders, not holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the
legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of
a security or has no choice because we are issuing the securities only in global form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a
notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so.
Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event,
we would seek approval only from the holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations For Indirect Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check
with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise
in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may
not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under the section entitled &#147;Special
Situations When a Global Security Will Be Terminated&#148; in this prospectus. As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities represented by a global security, and
investors will be permitted to own only beneficial interests in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another
institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will
be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held
through any book-entry clearing system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations For Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial
institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in a global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in a global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security
will terminate when the following special situations occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a global
security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions,
block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the
terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of the underwriters, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive
from the sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any
public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the
underwriter, the nature of any such relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We
will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts
basis for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional
investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide agents
and underwriters with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and
underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we may
offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. We cannot guarantee the liquidity of the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in over-allotment,
stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions
permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the
over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are
purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters or agents that are qualified market makers on the Nasdaq Global Market may engage in passive market making
transactions in the common stock on the Nasdaq Global Market in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock.
Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such
security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market
price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received
by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP will pass upon the validity of the securities offered by this prospectus, and any supplement thereto, unless otherwise indicated in
the applicable prospectus supplement. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our
financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_13"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the
Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should
refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Because we are subject to
the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s
website at www.sec.gov. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom508302_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed
with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the registration
statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36579):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501756/000162828023009899/advm-20221231.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A> for the year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1501756/000114036123020185/ny20007145x2_def14a.htm">Schedule&nbsp;14A
</A>, filed on April&nbsp;25, 2023 (but only with respect to information required by Part III of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock set forth in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1501756/000119312514282544/d765259d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on July&nbsp;28, 2014, including any amendment or report filed for the purpose of updating such description, including any amendment or report filed for the purpose of updating
such description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1501756/000162828021003623/advm-20201231xexx42.htm">Exhibit 4.2</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on
March&nbsp;1, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports furnished under
Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the
registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement, including those made after the date of the initial filing of the registration statement of which this prospectus is a part and
prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus, which will become a part of this prospectus from the date that
such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any
information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later-filed document modify or replace such earlier statements. We will furnish
without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference into this prospectus but not delivered with the
prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adverum Biotechnologies, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100
Cardinal Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Redwood City, California 94063 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">(650)&nbsp;656-9323</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g508302g27s54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen
</B></P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May&nbsp;11, 2023 </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g508302g01p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g508302g01p03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:@4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!8 Y!         "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M $@   %#    !@!G #  ,0!P #  ,P    $
M 0             !0P   $@                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   $@     4F=H=&QO;F<   %#    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      ,!0    $   "@    )
M >   $.    +Z0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ ) "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]2LL956ZRPAK& N<X\ #W.<N;Z=G9[,W%ZCEV/\ L?6R]E=+C[*#.[IVQOYO
MVG';^D_X5ZN]?<<IV/T6LG=U!Y^T$<MQJX?DZ_F^K_,?]<6?G]1/7:K^D]+Q
M'%U1;NMM>P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ 2 %# P$1  (1 0,1 ?_$ !X   $#!0$!
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M0Y 4<*!= #@#@=;R0E+G:1L]ROZAX41\'6B//[#9\?._'K6Q\4!?@?\ B?\
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ME.D!*0H]V_V'<05'>M[5\'9.CGNH!;^@]_'T^G\_OSYHXLB AKY9@>"#9)L
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MK<:2W#9@O2&VE!'MNN("<QVG&9\AI\S'AA&1,L4<<JH5B#6A.^*@VRQL1=G
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M9=(;^W>?CQ9M/@LEF-53@EF;7W-A*:!CNAP@\TN%-.T2;/<;9Y1(T4FRG5#
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M-%)DZAW#VYBQ1BRV1JN)CJHH-N=YI5C1>&Y9PM \<$]!$^HKUQT'.%.]T?\
M2J[.Y:S3D"UC4&53<*+UG$:@Q)BONZBJMX+[]=)9M%% G3U*^WCUS;[;JW2X
MAIHDTC2&PKS,Y_3<J9425J:+\DJ@AXU,;*R6 7W*#M&T\K6;XP_%.'NS'_\
M9UV&)-;DUO*.F:IJ>DP_CL*#%S&R-*R/2S-.GG9XUDEBE:88N1C)$ S+(D\<
M<Y1^B+I\=Z9>G# N*9OV4O((C'ZYF3K7NO-JR;)G&[/((\53S33JH<*4X["@
M(?[E-08T1K26TH:;@]6RES<N1_4DD5-T49D;=:*[D;22U*2Y*@!1_4]=T^&?
M:,_8_9>B:(RH)TQ<2?.HV#F-AXT,Y+K!C!VA$ B#E"=D8&YJ!Z[+K!'_ +J?
M4B1W$#@+EXZ5LDI.!WI 5YVKQK8!W^P((WZUZ2/^EL >!^(@4@_3UX^*(-\6
M#?L>G7Q,L?#SO@HWS+VCW(11/-:/F>""#[?46:Y'GH?/T/RM72#E_<HJ4.;\
MP2"-@'6+X3H@:3\D CQX\$'SZG>\E1=3Q0B!%.+%:@+[S9 .X GD\;O?^$CS
M?$_V39I9?AQK32R-)(.[L\;R6W&M%T&BNY58*#^7R+)*FB"3-IWVIWLGM&R?
MG>OW_P!?0J?)_4^/'\NK1KX'Z#_AUEZ\Z]Z$?]9TN#HNLSLD?XIX$ %G0/\
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M.TA('QZY\KE69I) 222=[EK!-\EN;H-?-U?TOJYQ1678J^F%'RB(!"H' V@
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M[AA#3Z692FG>QT("V'VRH.MI"PZH$J3/=W8N7E:CBLN.2!! [!8'8$"2<%>
MPW$F_(H$> >N1_LTSX6F?#G(Q<C-TXR1]PZF26R$"J/PV 5"AVBM8U4(^Y2
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M7 )LC\QNBI%^X!'!'TKBO''4;*L#:OKQ78';HVSSCFNTI*D\#TZ@5 [VA6U
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MH;C[3JF($/<BX8ALE*(UU.ESV2U/D.K5))J1CPGQ40@O&8V/A2&&TMPP.X>
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MX[1[&[;[(P5P-#Q$C.V,39;KC-F9DL*11C)RIX<>!I9V]!7:3:J[R[*@+6'
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MI[M=V@HDZV?))/D^DLJF@K \708&O -@'BN+]J'GCKPJ"=Q + 4"0+ %\7Y
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M6SI]/:-B5']Z%-=/GRTKW5-'7.CQF6:?U\"6'(Q[D2II<82&-<DM&Q=)&?\
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M$C;P/)&VFH@*-Q/3D?;*F2TL))4V6U:3V(5M/:2$%3G:D[\)*ED#P2K7HG9
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6H=9^LAP/K]SY_GU[U7I=+JO2Z77_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g508302g27s54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g508302g27s54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<D4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      -Q    !@
M    Q0   W,    > $$ 1 !6 $T (  M "  4 !R &\ <P!P &4 8P!T '4
M<P @ %, =0!P '  ; !E &T 90!N '0 +0 Q     0
M       !              -S    Q0                     !
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M;&]N9P   ,4     4F=H=&QO;F<   -S     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    $.$))300,      Q8     0   *
M   D   !X   0X    P\ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  D * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M7%U+@3D7/;2:K*SOK>RGWW_2;_HZTX#3SW:^60
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( #\!&P,!$0 "$0$#$0'_Q  >   " @(# 0$
M        "0<(!@H!! 4# O_$ $T0  $%  $# P$$! <,!@L   ,! @0%!@<
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M5AVV;Q$%,D .%^)4=2?/'<9)CP.&6)/F#R*:]3>>K77;:732!C/MW9B_;>Z
MA+UVF AMW*\ZJ.#W5OL_$(Y;F&;*6D!#AUT] (1QQ# %C1A"QHQ#8U&L&-B(
MU@V-:B-:QC41K6HB(UJ(B)X3I&\GDGR222?RDGGD_G_*?J?.KEJJHJJH"JH"
MJH  "@<  #@  #@ #@#Y:J]WO?E![E?W+<@_V>F=2>%_#.*_7ZW[0:YSU@_%
M7U"_BAGO]GSZ2-V*Q/4R+VXY1_;59<21N)5M]6E(+6,HUNTGIH9Z7:R%FP3R
M/C6U^J6/[R*GP^SV(C?"=.V<.VOM&7[2%SWOTX>\P]_IE?27T^.U@.0G ;\^
MJ?\ 1N/VAWV%CCT]L;6BVO[YE!37*+3:[ZXOS^^F3UH&D[3:]7T^6([.W@
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MCD'CP>R(1J3\^\R<D_/6K[,6VKS87/\ 4S/AY,]U!RMFXLTO)9<5#9E9&C#
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MD1/>B+7V@IM:1/ 0%D:6>PTF)M<*"].<EZTOEAV\\^D[<<&1 0>>?C0JX^9
M;^BG5BIU/VVKV3%5W5B!'5W#C !$PFX[4R-:!I'D%*V58?%_[O:2>JQ/9&\E
M\NH+7:-(B]4SZWA;N=[.^ZX<4KJ++Z*+FM-*BA8AD!1Z$>A2 60I5<];7/V^
MF#% X0VM;$E^#N>?P!ZVMQ=QF9Q)/W26-I85)\<R1&/N'^!(D18\\GN4<$ \
MTO\ :3];:'47I1U-6-_<<=>BQ^2FB50XCH9!,A[NSGDNUO'V\JD,?:./1E[6
MYD)5X]#=U&EIJJ_H;&);TMS7P[.JM()V28=A7SHXY,.9%D#5S# D (PHB-54
M<UR+TCNCQNT<BE'0E74C@JRD@J1\P01QQJX].Y5R%6M>I3Q6J=R"*S5LP.LD
M,\$Z"2*6*125=)$8,K*2""#KUNL=;.E%>LCRI7YSMGA\11#CE;'F;7YRKJJ$
M'QFLI-/G;:+?6$\47P\ZA;:0Z.L8036N?*L@B8YR?(Q6W9U5Y,FUL@K#2@E=
MY#X4/(AC52QX /8TC^3X"$D:JY[6&Y:^/Z=Q;7C<2Y7=F6Q\%>DG#V)*>-M0
MY">=8@"Y06X:-4%0"TEE$7D%P&%]N/'I>)^!>(.-Y(A@G8WCS*T=H,2D5GVQ
M%IXOVR]OR&.Y$+:NF%5J%>QJO5HO:)&-:OY&R+E^Y:!)6>S-(G/S[&<]@\ ?
M).T?+Z>?/G7==@X%]K[)VIMZ1%2?$8#%TK2J25]\BJ1>^,.YY#\=HS-P'*CN
MX3A0 (C]07\EG<;^[>S_ *S#ZV]O_AO&?K2_R'TJ]=/Q1;^_@&;]M!KJ^G@G
MGLF[=$_GX]CI_GL[-.LMQ?AO)?K!_D)KRZ"_B?V#_ B_SNSI>F=)_<,^I];9
MDKG5W"_>& ,VG  9&5=5M+6T*L!BC1&QV%@[!]I6#$%49"IMA"*]K!C1J3\G
M.<VPDO'==PQ*L?F[PHOQ'D^>&@[6^O+0/Q]1KAM CHS[1EK'L37VAU8C26HB
M!EK5<O:M-[NI'A \.9:U45$^&&GF:Q;M XUZV4:O>]ZFEWL#@'9\*=G,;['H
M2M5IJRTWX9YV19;2(UXY!CZ:-8W '#<HE@9"J1ZN^5?EQEXP>V$A#=E[-'OD
M'D.E=N"01]/N)6,@\'NG<CGYC9Q@_HQ>T3=RLD:V=H=)8Q4HL.'KV<W'/*L4
MH;@J[/E(K5M&C8JT&'I%O$G!M!ZM*>.Q3EE$_!+'CM/\W(68ZB]J?ARK_@6?
MYO+KI'M._B8W1^M;=_WBQ>IL["?R9]MG[J,Q_55ZTL[^&,C^M2?Z]-_1;\5&
MP/XM8[]F=5-;V\\L<T>IA:<T\JY6;3\-\ Y^J@\0R);PFK=9<E@K(ASX(U(5
M'N@W%K>7<\[!A)"FUM##+Y>Q'=2IR-.GME*5256NY"60W0 0T48;M8,2!]\B
M1(@Y(*M(P^9YY@-B;GW;[0UG=^Y<9+4VELBA5AVM)*4>#*6S#ZD$L [G#&&Y
M;OWK,BK&\,U;'P-RR]P;4B>$1$_!$1/\W2IJSVOR40S#>(K&D&1JL>Q[4<Q[
M')X<US7(J.:Y%5KFJBHJ*J*BHO1^@\'Z$?,?GU\(# JP!4@@@@$$$<$$'P01
MX(/@C2INZGTI^(^9Y4W><.2V\&<M*\TYECGAFC8^]L3.]Q"7-'7J(E1).BE:
MMKFG0GH0YI$ZNM2*C>FK%[JN4E6O<'O]3P.R4@S(HY\)(P/>H\$)+W < (4U
M6CJ5[-&UMVR2YK:<HV7N?N>99Z"O'B+L[L"S6Z4!1JDKCN7WK'&$EI&EL5KC
M #45>E?P?W3=L>]YDX>Y<Q$NNXTEP8&JI-0"PB6&7DZP<H56KL[. 9SI:7U(
MU#6(' !-K_L6N2RBQ"R&#+M;INXK)5Z5NG85[2LT3Q=K+*(2"_W52/A,;^%/
M)#>HW:2!SI;]FW9_4GIYG-V[5W1AI:VWIH*^3JY%)X;&-DRR2K5YQ\T;]TWO
M]+XYU,<<L HUQ9B@DD5'=5*&XL62)OA7$CF&U%7PBN>-S4\K^Q/*I]_[.DP>
M"#^0C5NG!9' ^95@/TD$#6N=VLL]2#LTR>QXTQG:#$VU9<<@W6L+=7%FQZOE
M28-32J.O+4Z>''/6O#1ADQCN&I"_4.=Y]BL:WHF5.V\S-%9GS!@9(%B"(H'"
M]SR<N)(RP;F0@CY#CZ\ZH/TU7V@.DV*RFWL1TLBR]>UG+63>W;L(_,K5ZE$K
M7>KE(HWKE**2QN5+/ZC'D#@:LT7NR]54HR"C=B^7CR"L<,$@\^>\(#$:K!&*
MQVV"UXQ/5KWL<437-:K5(Q%]R1HQ6T^1SG92!Y( 3D@>2!Q"QY(^7 /Z#KHC
M=3?:7966/HUC$=@51WFF*(Y'"LX.;0%5/!8%T! (++\QB5WVQ^I-WD/;1]SG
M)>2X)XBDR6'N<#Q\Z#.L+0(C+XAECT<ZP98@(UB$8W2;.?#BD^"4VHD2!JQO
MJF3VSA^7Q=66_; /98L!E121SR#(%[6Y\,8H$8\$!U!!U&7.G7M!]6"*?4;<
M.+V7M:24/;P6#,$\UA$8D1-%1GLI9C8*& R.:L11/V2BG(Z]H;!P%V_<8]M?
M'M=QOQ91,J*:(J2;&<=PY%WH[=XV#DWFALFB"ZPLY+1L8K_C%&C &&' C1((
M 1A*E_(6LE8:S:D[Y&\*H\1QH"2(XUY(5 23QY)8EF)8DFS6R-C;<Z?8*#;^
MVJ0JU(CZMB>0K)=R%ME59+N0L!4-BS(%52>U(XHU2&".*"..)9KZTM-^CHT:
MUKNYCL9[C!]S>]XMX7S^C!V[=TVQQVPV%_7,/(S&:)66<FWT(]%("1H*UE+;
M3;>WK(4YJ+9QRU<*M=)E"^)G2<9GL<<97M798SDL5%-#%&Q FE[T6-/3!'Q=
M\:HCE>>WAG?CGG7Y]]0^C._UZBYO;>T:6038?4K+8G*Y6] LDF,QS5[4UN\,
MA(I[*ZT;EFY=JP3]ILHU6O7,DD9 V*\9DJ3!9+-XK-P@UV?RE)69^F@@;[!1
MJVIAA@Q!(GE55R! Q7O<JO(17/>YSG*Y>=32O/+)-(Q:25WD=B>26=BS$D_G
M.KZ8G&4L+C,?A\="M>ABZ5:A3@0<+%6JPI#"@_*0B#DGDL>6))).LFZ\]2&H
M$[IL7HN1NW'G#!Y&"EGJ-=Q?L\_GZ]T@$5)UM94DJ/!B?4R7BCA60=[!-(<@
MQ-<Y%>]K?+DWL7-'7R5"Q,W9%!;@ED;@GM1'!8\#R>!Y\>>/ES\M)74?$7\_
ML'>6$Q<(L9+*[;S%&C7,B1>O:L49HX(O4E98T,DC*@:1D0%AW,H\A+G;!L?4
MN[7>'J'AW+]E\324]%/O;"/;7T]X[([[ZWEVYV&;7ZN-%1@#2WB%[!(Y1L:K
MU5WE>G3)Q;:R=R2W-FO3=UC3LB *CTD" @O'W?$ #_\ S51^G>5]H7ISM6EM
M7&=(X[U2G/>L)9OS<67:];EMNKBOE8X@$:4HG:O)4 L2>=6#_NMO5/\ Z".<
M_P!(V'_&74?]E;4_N])_DC_[K3Q_1/\ :5_O,8[_ $\__C.C^ZV]4_\ H(YS
M_25A_P 9='V5M3^[TG^2/_NM']$_VE?[S&._T\__ (SIK7%-[M=/QOBM!R/E
MPXG=V^=K)^KR0)39@<_>2(PR3ZP<EI3H1D8ZN:B*<SQI_%$*1['/55M1PQ69
MXZTIGKI*ZPS$=IDC!^%^.!QR/GX'GSP!JS.V;N8R.W\/>W!C$PV;MX^M/E,4
MDHF2A=DC5IZRR*\@81N2 /4<K]Z7<J6*S.\O@/EOD#OO[*N3L=C+*^PV(M:-
MVPT,-0?19L=#MG:*<:V>4HUC")6%]\)51RS9 R1([7R/8-[-ALA4KX+-U)ID
MCGGCD]&-N>Z4R0>DH3@$'XAPW]J"&/P\D5WZM;'W3G>M'2+<.)Q%B]AL1:QY
MRE^$Q^ACEQV;&3L/;+,IB5ZIYKD@B:56A3F4JK-TZ4=6DT+]Z*G\_1HTD?N:
M[5.:^ .Z#*=W'9?E9-^367T>LY7XKIE9'@6![<K!VE@>O$Z#$_1K0)_UJXD'
M,[]']*T.D1P@/<2 [8S*TLABY<1FIA'Z4?=4MN.YU5!\"!SW'U8_ 0 ?=(N8
MSR1YI]U%Z:;OV-U%QO5+I'C);[Y.ZL&YMLT^V.">2XX%J9ZZ-7C^S,B0);CO
M(QH901Y0\1]SUG91GE)'"0P_A,\;'%#[FO41'(BN&KV_JO5BJK5<W[G>/*?<
MO22>.3P>1R>#QQS^?@_EU;]2Q52R]K%067D-VL0.5Y'@\'D<CP>.1XU#O<#P
M5B>X_BK4<3;V.1]-HHJ?36$9H5LJ&XC.^6KOZEYQD&*PK)*-*)7-49Q./$,C
MH\@S';N/O38ZW%;@([XF\JW/;(A^_C?@@]KCP>#S]=*F^-F8??VV<EMC-HQJ
M7XQZ=B()[S1MQ\M6O5&D5U2Q6D^)2RE74O%(&CD=2G+&Y;U*?3\^IQ&$QM?W
M5\"5U@0N;CQ5F2[^HJRF][H=361;!=+G"E^7WGK!0-1GXLM3R(/E"R"%<)I=
MM;@XGGF;$WV7B4GM"2,.>6=V412^!X=FBD8< _>@&J.)QOM"=#?4PV&Q-?J7
MLB&RSX^.'UI;M6L[]QCJUHI_M+',_<3)62#+4(IB\L'W[&239W?EZ@VBCOI\
M;Z>.OS^AFM>*!;:O]+#T<,J#>]33&3*#)1?#4;[A_/>PQO(C0HI'D8Q=88';
M\1#S[B@EB4 ND)@$C>0"%[99F^O/B)CQS\OF&&7K9URR"&IB>@V5HY"<%8+6
M4^UGI0L%9B\RSXW#PG@#X1)D8 6 4!F8*<A[;.Q+F?8<U5O=EWPZV%JN3J<H
MSXOC:O=!FT&2+#1RU$B82"UU)'^Q#/?.JJ:@86..U^.ZGVTRP^<9//)9VE#1
M;$X*%HJK@B>RX99)N?OPO?Q(?4^]=Y.T]GW-$5#K?Z?]%MW97>$'4_K)E8LE
MN.JROB-OUV@GI8MH>33:9H>:,:T79IZM&@)8A;[;]BY-:]0.X?I/U:O58.]+
M&Z?D+M5YSQ6,IY6@U.BP5I!I*6%\7UEE,1X)#8L5IB"82008"($7O1YB>T0D
M<1[&K)X6:*OEL?/.XCBBLJTCMSPJ\,O)X!\ D<GZ#DGY:YSU=Q&2SW33>>(P
M]22_D[V%L14Z<)02V)0T<GI1>HR*TC*C!$[@7;A%Y9@#\>R7$:GCCM1X,Q&V
MII.>U>>P\.'=TLQP72ZV6^7,E?2R?@*8;#L#($I1(17A>KA%1A6/8W[FYXK6
M5O3P.)(I)V9''/# !1R.0#QR#P?J/(\:\^CV&R>WNF6S,-F:DE#)T,/'%<IS
M%#+7E:::41R>FSJ) DB]Z]Q*,2C ,K 01ZF7:WH>Y/@N)(XY@/E\N<87X-?A
M613AA6=@)49&OJ*OL3%CI$DRXS8MK"\20J6THZ\+'->1%3>VUE(\;>86&[:E
MN,PSD@LJGYQR,H!Y4'E&\'A'8\'C2=[0W3>_U!V9#)@*YFW3MN\F4PRQND%F
MQ&P$5^C7L.\0AEEC$5N'[HG?:HUT#*S!AE7IT=L\_MD[<J.@U=:R!R9LYLG:
M<CJXPI<H5U8N4==3R982G$9U%2CA0SH$YH_VFZS.$C_J7O?Y;BR:Y/)221/W
MUH56"L>.T%%\NX4@$>I(68<CGM[>?EJ2Z#=/9NG>P:5+)5Q!N++S29?/@NDL
MB6YSVUZCRQLZ,:5-88I DCQ>]&S)&Q67D]CU(^--QRWV?<I8GCO/S=3JYC\G
M8P**M:TEC8AH]A1V]@* !51TJ6R##D%#%'Y-(<SX@M>5S&.^;<LP5,O5FLR+
M%$!,K2-SVJ7A=%+$ \#N8 D^!\SX!UZ=?MO9G='2K<F'P%";)Y.5\18AHUP&
ML3QTLQ1N6%@0D&658(9'2)>7D*]B*SE5,M=G^+TW'7:_P5A]E5EI=3F>-\Y5
MWM0<@2GK;$,1JGAG?'(4*GCN?\9FC(]&$:YGN56KUJ9>:*QD[T\+B2*6Q(T;
MCGAU)\,.0#P?F#QY'G3/TMQ.0P/3K9N'RU9J>2Q^ H5[M5V1I*\ZQ O#(8V=
M.^,GM<*S ,".?&K(=1VG[1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1
MHT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C
M1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HU771\J;>#H^0(5/"XS!1
M<?FB FR]CM+3/64UQ\I4ZD\@8XV:M842$$5LR(D@YW^71C$>UC51&MM/!XV6
MGB);$N;>UEUD>*/'8R"Y#$%R%BBB$O=@D>5S7+]BJ. Z*"3\TB]N++17LW%5
MAV]'3PC1)+)ELQ9H3S=^,K9)Y (\?9BBA1;(C]1W;S&[$ ?*9<;H?TNR>;U/
MV=-J/TBHJJ[2JLF(.PK4M($>:D&:-$3VR8OS_"9/"?KL7[D_!%W(5#0OW:)F
MBL&E;L53/ >Z&;T)7B]6)C\T?M[E/D<'YG33B[OVEC<?D?0EJ^_TJMSW:=>V
M>#WF%)O1E7Z21]_8X_M@=="KU![#=[#).BC''S-)CK04MI'.+*+IRZ=AAD&K
M4:-D5M 'XE:YRO4Y5?X1K$3VGHK#B\?D!(S-=LY&!HR %C6DM$JP;YDR&TW<
M#X':O'S.O"OD'GR^3QIB54H5,7864,2TC9!L@KJR\ *L8IIVD$EB[<\<#77Y
M#VC\330I$*K+>WU]=5^8RU(([8C;306OS.B!ESG".VOK8T>-+LK:P4$AT*L@
MRY HLLS!Q39XG&_:5B5))UJU:M:6]>M,ID,%2#M$C1Q J9IY'>.&O#W()9Y8
MT:2-"TBX9K+?9-6%XZSW;EVW#C\=31Q%[S=L!S&LDQ5A!7BCCEL6I^R0PUH9
M72*5PL3X="VW(6<T>;IN2:3,I6;.S+34E_C9MJ>/57R5TFTC4=_!N(<>0X,Z
M-7V(H&@AE:"1- "++JJQ\V.K]^3&XJY4N6,-9O>MCH%LV:F2BKH\]7UD@DM5
M):\KIW1/-"TU.1>](V>2.>PL;\1D.5S=&[1JY^GCA!E9VJU+N)GM2QUKGHO8
MBIW8;<,;]LT<,ZPWH6$<DJ+'+5K&:/F6[AUNRKG.H UTBY;'>M<&VD28E:25
MX_BVS9$.+-E! J_RW@BG(B?R6*O4% (#-$+33)7+@3-72.2=8^?B,22R11LX
M'R#R*I^ITR6C:%>8TE@>T$;T$M2215VDX^$3211S2(G/WS)%(P'R4ZB+C?7\
MJ:BZO0:>@P5;2YR_M,U8'HM#H;&S+808,&6(\6-89FMBNB$=/$,GS2PG8C"/
M:,GAK'3V8Q^#I5JCTK>5GLW*L%V)+5.I# L,LTT3+))#=G<2KZ+,H6-U/(!8
M>2%K!Y/<60MW4OTL+!4H7K&/GDIW[T]@SQ003*\44V.@C:)C856+RQNH4L%;
MY:S?DK62<+@M9L(<*/8RL]32[*/!ER7PXLDP&I\8I,L8))(X%<J*4K(YGL8C
ME:QR^$ZCL-03*96ACWE>%+EF.!Y402/&KGXF2-F178#GA2Z@GQW#YZEL]DGP
M^&R64CA2Q)1J364ADD,,<C1KRJO*L<K1H3QW.(W(7DA3KPL9>\BV=NZ/IQ\8
M)5MB%(KL?J;NYM&R&N&T*NB3\_71TBN]ST*592/8_P")&#>CE\;&1K8B& -2
M;-^L9%'&1H5:T!0ABW$D-R9S(.%X7T^TCN)8<>=/%7,Y8LE,@FW?=Q$[$XK)
MW+=D."@3F*>A73TCRP=O5!![.%/)UE.ZUT+"9.ZU<^-+F@J(J$' @"4TZRG2
M3"AUE9#&B*BRK*RDQ($=S_:)AI#'F>P+7O;IXS'RY2_6H0O'&]B0J996"Q0Q
M(K233R$__#@A225P.6*H0H+$ R&7R<.'QMO)6$DECJQAA#"I>:>:1UAKUX5
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M\Z_A_P#/I?TSZK1A>?SZWC[8Z"PSS<]L,ME[C7ASLF4^3#N,Z*+92L_?UDY
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M20.KRSE+#<\:[;(5*UOVGH<]85L!MPXK*I\HXE^$5D\$:89D(KT04EXHDI[
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LFF.7-9XY9W:FR/[N;1-3PB)Y\^/V_P#E5_U])0\ :Z#KGHT:.C1HZ-&O_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
